Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus PHENERGAN W CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus PHENERGAN W CODEINE.
METHADOSE vs PHENERGAN W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Promethazine is a phenothiazine derivative with H1 receptor antagonist activity, antiemetic, and sedative properties. Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting pain transmission and causing cough suppression.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
10 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4 to 6 hours, not to exceed 60 mL (codeine 60 mg) per day.
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Promethazine: 9-16 h; codeine: 3.5 h (terminal), prolonged in renal impairment (up to 18 h).
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Renal: 70% (codeine as unchanged and metabolites, ~10% as morphine-3-glucuronide, <10% as morphine); biliary/fecal: 30% (promethazine as sulfoxides and glucuronides).
Category C
Category D/X
Opioid Agonist
Opioid Agonist